• No results found

Bioactive properties and clinical safety of a novel milk protein peptide

N/A
N/A
Protected

Academic year: 2020

Share "Bioactive properties and clinical safety of a novel milk protein peptide"

Copied!
8
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Nutrient content of milk peptide product(per 100 ml)
Table 2 Participant descriptive data.
Figure 2 Comparison of HT-29 human colon cancer cell death between commercially available whey peptides and the MP mixtureHT-29 colon cancer cells were incubated with 0.68 μg/μl concentration of commercial hydrolyzed whey protein, MP peptides, and vehicle
Figure 4 Neutrophil to lymphocyte ratio values observed forthe placebo (P) and milk protein (MP) groups over time.
+2

References

Related documents

Generally, from the present study we can conclude the widespread occurrence of CAV infection in commercial broiler breeder farms at least in the three states of Malay- sia. Detection

means we are left with language and the object cause of desire as a real void.

with the focus on small and medium enterprises were mapped out. In connection with these communications in selected Member States there were established facts in the area

Methods: Stereoacuity testing was performed in 28 children with IXT and 25 age-matched control subjects using the SC test, the distance Randot stereotest for distance, and the Titmus

influences the perception of a contract it does not influence the effort choice compared.. Multiple

The main fatty acids of papaya woton fruit extract ( Sterculia tragacantha ) were methyl palmitate and methyl tricosanoate while the main amino acids are L-Arginine,

Although there was no significant difference in cov- erage levels in 2000 or 2005, the 4:3:1:3:3 coverage levels were significantly lower for AI/AN children, com- pared with